Tricuspid Valve Dysplasia

Tricuspid valve dysplasia (TVD) is a congenital cardiac malformation characterized by variable morphological abnormalities of the tricuspid valve apparatus, including the leaflets, chordae tendineae, papillary muscles, and annulus. These structural defects lead to malcoaptation of the valve leaflets, resulting in tricuspid regurgitation (TR) and, in some cases, tricuspid stenosis. The severity of the malformation ranges from mild thickening and mild regurgitation to severe leaflet hypoplasia, fused commissures, and markedly dilated annulus, causing massive right atrial enlargement and right-sided congestive heart failure (R-CHF). TVD is one of the most common congenital heart defects in dogs, particularly in large breeds, and is occasionally reported in cats. The disease is typically diagnosed in young animals, but mild forms may remain asymptomatic for years. The clinical consequences depend on the degree of regurgitation, the presence of concurrent congenital defects (e.g., atrial septal defect, pulmonic stenosis), and the chronicity of volume overload on the right heart. In severe cases, progressive right ventricular (RV) dilation, right atrial enlargement, and eventual right-sided heart failure with ascites, hepatomegaly, and pleural effusion occur. The condition is often progressive, and management focuses on controlling signs of heart failure and slowing disease progression with medical therapy, with surgical or interventional options being limited and rarely performed in veterinary medicine.

The exact etiology of tricuspid valve dysplasia is not fully understood, but it is widely considered to be a congenital developmental anomaly arising from abnormal embryogenesis of the atrioventricular valves. The tricuspid valve develops from the endocardial cushions and the ventricular myocardium during early fetal life. Disruption in the complex signaling pathways and genetic programs that govern valve formation can lead to the morphological spectrum seen in TVD. A genetic basis is strongly suspected, particularly in certain dog breeds with a high prevalence, such as the Labrador Retriever, Golden Retriever, German Shepherd, and Weimaraner. In Labrador Retrievers, an autosomal dominant mode of inheritance with incomplete penetrance has been proposed, and a genome-wide association study identified a locus on canine chromosome 9 associated with TVD. However, no specific causative gene has been definitively identified. In cats, TVD is rare but may occur as a sporadic congenital defect. No infectious, toxic, or nutritional causes have been identified. The condition is present at birth, although clinical signs may not manifest until later in life if the regurgitation is mild. The morphological abnormalities include thickened, nodular, or hypoplastic leaflets; short, thickened, or fused chordae tendineae; abnormal papillary muscle attachment; and dilation of the annulus. These abnormalities prevent normal leaflet apposition during systole, leading to regurgitation. In some cases, the valve may be stenotic due to fused commissures or a hypoplastic annulus, but regurgitation is the predominant hemodynamic lesion.

Tricuspid valve dysplasia is one of the most common congenital heart defects in dogs, accounting for approximately 5-10% of all congenital cardiac anomalies in this species. It is more frequently diagnosed in large and giant breed dogs, with a notable predilection for Labrador Retrievers, Golden Retrievers, German Shepherds, Weimaraners, and Boxers. In Labrador Retrievers, TVD is the most common congenital heart defect, and a familial predisposition has been documented. The condition is also reported in other breeds, including the Old English Sheepdog, Irish Setter, and Great Dane, but with lower frequency. There is no strong sex predilection, although some studies suggest a slight male predominance. The age at diagnosis varies; severe cases may present in puppies as young as 6-8 weeks of age with signs of right-sided heart failure, while milder cases may be detected incidentally during routine auscultation in adult dogs. In cats, TVD is rare, with only sporadic case reports; no breed predilection has been identified. The prevalence of TVD in the general canine population is estimated at 0.1-0.2%, but among purebred dogs screened for congenital heart disease, the prevalence is higher. Geographic variation is not significant, but breed popularity influences the number of reported cases. The condition is congenital, so no environmental or seasonal factors affect its occurrence.

The fundamental pathophysiological abnormality in tricuspid valve dysplasia is the failure of the tricuspid valve to coapt properly during ventricular systole, leading to tricuspid regurgitation. The regurgitant jet from the right ventricle into the right atrium during systole imposes a volume overload on the right atrium and right ventricle. The right atrium dilates to accommodate the regurgitant volume, and the right ventricle undergoes eccentric hypertrophy and dilation due to the increased preload. Initially, compensatory mechanisms such as the Frank-Starling mechanism and neurohormonal activation (renin-angiotensin-aldosterone system, sympathetic nervous system) maintain cardiac output and normal right atrial pressures. However, as the regurgitant fraction increases over time, the right atrium and ventricle become progressively enlarged, and the tricuspid annulus dilates further, exacerbating the regurgitation in a vicious cycle. Eventually, the right ventricle fails to cope with the chronic volume overload, leading to increased right ventricular end-diastolic pressure and elevated right atrial pressure. This results in increased systemic venous pressure, causing hepatomegaly, ascites, and peripheral edema. Pleural effusion may also occur due to increased hydrostatic pressure in the pleural capillaries. In addition, the interventricular septum may shift toward the left ventricle (paradoxical septal motion) due to right ventricular volume overload, which can impair left ventricular filling and function, although left-sided heart failure is uncommon. In cases with concurrent tricuspid stenosis, there is impaired diastolic filling of the right ventricle, leading to right atrial pressure elevation and similar signs of right-sided congestion. The severity of clinical signs correlates with the degree of regurgitation and the chronicity of the lesion. Arrhythmias, particularly atrial fibrillation, may develop as a consequence of severe right atrial enlargement, further compromising cardiac output.

The primary predisposing factor for tricuspid valve dysplasia is genetic predisposition, with a strong breed association in dogs. Labrador Retrievers, Golden Retrievers, German Shepherds, and Weimaraners are at increased risk, and a familial pattern has been documented in Labrador Retrievers, suggesting an inherited component. The mode of inheritance is likely autosomal dominant with incomplete penetrance, meaning that not all animals carrying the genetic mutation will express the disease. Other intrinsic factors include the severity of the anatomical malformation; animals with more severe leaflet dysplasia and chordal abnormalities are more likely to develop significant regurgitation and clinical signs. Age is a factor in that clinical signs may appear early in life in severe cases, but mild cases may remain asymptomatic for years. Extrinsic factors are not significant in the etiology, but concurrent congenital heart defects, such as atrial septal defect (ASD), pulmonic stenosis, or ventricular septal defect, can exacerbate the hemodynamic burden and accelerate the onset of heart failure. Additionally, conditions that increase right ventricular afterload, such as pulmonary hypertension, can worsen tricuspid regurgitation. Obesity and pregnancy may also increase the workload on the heart and precipitate clinical signs in previously compensated animals. There are no known dietary, toxic, or infectious risk factors.

Clinical signs of tricuspid valve dysplasia vary widely depending on the severity of the regurgitation and the presence of concurrent defects. In asymptomatic animals, the only abnormality may be a heart murmur detected on routine physical examination. The characteristic murmur is a holosystolic, plateau-shaped murmur best heard over the right thorax at the 3rd to 5th intercostal space, near the tricuspid valve area. The murmur may be soft to loud and may radiate to the right apex. In severe cases, a right-sided precordial thrill may be palpable. As the disease progresses and right-sided heart failure develops, clinical signs include exercise intolerance, lethargy, weakness, syncope, and respiratory signs such as tachypnea and cough (due to pleural effusion). Abdominal distension due to ascites is a common finding in dogs with right-sided heart failure. On physical examination, jugular venous distension and positive hepatojugular reflux may be observed. Hepatomegaly is often palpable. In advanced cases, peripheral edema (subcutaneous edema of the limbs) may be present, although it is less common than in humans. In cats, signs are similar but may include more pronounced respiratory distress due to pleural effusion. Arrhythmias, particularly atrial fibrillation, may cause an irregularly irregular heart rhythm and pulse deficits. In puppies with severe TVD, signs of right-sided heart failure may appear as early as 6-8 weeks of age, including failure to thrive, poor growth, and abdominal distension. Sudden death is rare but can occur due to arrhythmias or rupture of a severely dilated right atrium.

The differential diagnoses for tricuspid valve dysplasia include other congenital and acquired cardiac conditions that cause right-sided heart enlargement, murmurs, or signs of right-sided heart failure. Key differentials include: 1) Ebstein's anomaly, a rare congenital malformation characterized by apical displacement of the tricuspid valve leaflets, which can be distinguished by echocardiography showing the septal leaflet attached to the ventricular septum below the atrioventricular junction. 2) Atrial septal defect (ASD), which can cause right heart enlargement and a systolic murmur, but the murmur is typically a soft ejection murmur at the left base, and echocardiography reveals the septal defect. 3) Ventricular septal defect (VSD), which produces a loud pansystolic murmur at the right sternal border, but the defect is visualized on echocardiography. 4) Pulmonic stenosis, which causes a systolic ejection murmur at the left base and right ventricular concentric hypertrophy, but the tricuspid valve is structurally normal. 5) Tricuspid valve endocarditis, an acquired infection causing vegetative lesions on the valve, usually associated with fever, positive blood cultures, and systemic signs. 6) Right-sided congestive heart failure due to dilated cardiomyopathy (DCM) or arrhythmogenic right ventricular cardiomyopathy (ARVC), which may cause tricuspid regurgitation secondary to annular dilation, but the valve leaflets are structurally normal. 7) Pericardial effusion with cardiac tamponade, which can cause right-sided congestion and muffled heart sounds, but echocardiography shows pericardial fluid. 8) Heartworm disease, which can cause pulmonary hypertension and right heart failure, but is associated with a history of heartworm exposure and characteristic imaging findings. Definitive diagnosis of TVD is made by echocardiography, which demonstrates the characteristic morphological abnormalities of the tricuspid valve apparatus and Doppler evidence of regurgitation.

The diagnostic approach to tricuspid valve dysplasia begins with a thorough history and physical examination, with particular attention to the cardiac auscultation and palpation of the jugular veins and abdomen. If a right-sided systolic murmur is detected, the next step is thoracic radiography to evaluate cardiac size and shape, pulmonary vasculature, and the presence of pleural effusion or ascites (on abdominal radiographs). Radiographic findings in TVD include generalized cardiomegaly with marked right atrial and right ventricular enlargement, which may appear as an increased sternal contact of the heart on the lateral view and a globoid or 'reverse D' shape on the dorsoventral view. The main pulmonary artery may be prominent if concurrent pulmonic stenosis exists. Electrocardiography (ECG) may reveal right atrial enlargement (P pulmonale), right ventricular enlargement (deep S waves in leads I, II, III, and aVF), and arrhythmias such as atrial fibrillation. However, the gold standard for diagnosis is echocardiography. A complete echocardiogram, including two-dimensional (2D), M-mode, and Doppler studies, should be performed. 2D echocardiography will demonstrate the morphological abnormalities of the tricuspid valve: thickened, nodular, or hypoplastic leaflets; abnormal chordal attachments; and a dilated right atrium and right ventricle. Color-flow Doppler will confirm the presence and severity of tricuspid regurgitation, and continuous-wave Doppler can estimate the regurgitant jet velocity, which correlates with the systolic pressure gradient between the right ventricle and right atrium. In cases where the diagnosis is uncertain or concurrent defects are suspected, advanced imaging such as cardiac computed tomography (CT) or magnetic resonance imaging (MRI) may be used, but these are rarely necessary. Cardiac catheterization is invasive and is reserved for cases where surgical intervention is planned or when hemodynamic measurements are needed. In asymptomatic animals with a murmur, screening echocardiography is recommended to confirm the diagnosis and assess severity, as early detection allows for appropriate monitoring and management.

Laboratory findings in tricuspid valve dysplasia are generally non-specific and reflect the consequences of right-sided heart failure. Complete blood count (CBC) may be normal, but in cases of severe heart failure, there may be a stress leukogram or mild anemia. Serum biochemistry may reveal elevated liver enzymes (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase) due to hepatic congestion, and in advanced cases, hyperbilirubinemia and elevated bile acids may be present. Renal parameters (blood urea nitrogen, creatinine) are usually normal unless there is concurrent renal disease or reduced cardiac output. Electrolyte imbalances, particularly hyponatremia and hyperkalemia, may occur with aggressive diuretic therapy. Blood gas analysis may show respiratory alkalosis due to tachypnea, but metabolic acidosis is uncommon. Cardiac biomarkers such as N-terminal pro-B-type natriuretic peptide (NT-proBNP) and troponin I may be elevated in dogs with heart failure, but they are not specific for TVD and are more useful for distinguishing cardiac from non-cardiac causes of respiratory signs. In dogs with right-sided heart failure, ascites fluid analysis typically reveals a modified transudate with low cell counts and high protein content. Urinalysis is usually unremarkable. In cases where infectious endocarditis is suspected, blood cultures and serology for Bartonella and other pathogens should be performed. Genetic testing for TVD is not commercially available, but research studies have identified associated loci.

Thoracic radiography is a key imaging modality in the evaluation of tricuspid valve dysplasia. On the lateral view, the cardiac silhouette is enlarged, with increased sternal contact and elevation of the trachea. The right atrium may appear as a distinct bulge at the craniodorsal aspect of the cardiac silhouette. On the dorsoventral or ventrodorsal view, the heart appears globoid, and the right heart border is prominent, sometimes giving a 'reverse D' shape. The caudal vena cava may be dilated, and hepatomegaly may be evident. In cases of right-sided heart failure, pleural effusion may obscure the cardiac silhouette, and ascites may be seen on abdominal radiographs. Echocardiography is the definitive imaging modality. 2D echocardiography reveals the morphological abnormalities of the tricuspid valve: thickened, nodular, or hypoplastic leaflets; abnormal chordal attachments; and a dilated right atrium and right ventricle. The right ventricular free wall may be hypertrophied or thinned depending on the stage. M-mode echocardiography can measure right ventricular dimensions and fractional shortening, but the right ventricle is not well suited for M-mode assessment due to its complex geometry. Doppler echocardiography is essential to assess the severity of tricuspid regurgitation. Color-flow Doppler demonstrates the regurgitant jet, and continuous-wave Doppler measures the peak velocity, which can be used to estimate the systolic pulmonary artery pressure using the modified Bernoulli equation (assuming right atrial pressure). In cases with concurrent tricuspid stenosis, Doppler can measure the pressure half-time across the valve. Advanced imaging such as cardiac CT or MRI is rarely needed but can provide detailed anatomical information if surgical planning is considered. These modalities can accurately quantify right ventricular volumes and regurgitant fraction.

Cytology and histopathology are not typically used in the diagnosis of tricuspid valve dysplasia, as the diagnosis is made by echocardiography. However, if a cardiac biopsy is obtained during surgery or post-mortem examination, histopathological findings would include the characteristic morphological abnormalities of the tricuspid valve: thickened, myxomatous or dysplastic leaflets with disorganized collagen and elastic fibers; abnormal chordae tendineae with irregular thickness and attachment; and hypertrophy of the right ventricular myocardium. In cases of right-sided heart failure, histopathology of the liver would show chronic passive congestion with centrilobular necrosis and fibrosis. Ascites fluid analysis, if performed, would reveal a modified transudate with low cellularity and high protein content, consistent with increased hydrostatic pressure. Cytology of the fluid would show mesothelial cells, occasional macrophages, and lymphocytes, but no evidence of inflammation or neoplasia. In cases where endocarditis is suspected, histopathology of the valve would show vegetative lesions with inflammatory infiltrates and bacterial colonies, but this is not a feature of TVD.

Treatment of tricuspid valve dysplasia depends on the severity of clinical signs and the presence of heart failure. Asymptomatic animals with mild regurgitation may not require any treatment but should be monitored regularly. For animals with clinical signs of right-sided heart failure, medical therapy is the mainstay. The goals are to reduce congestion, improve cardiac output, and slow disease progression. Diuretics are essential to manage fluid accumulation. Furosemide is the most commonly used diuretic, with a starting dose of 1-2 mg/kg PO q8-12h, titrated to effect. In severe cases, furosemide may be administered IV at 2-4 mg/kg. Spironolactone, an aldosterone antagonist, is often added at a dose of 1-2 mg/kg PO q12h to provide additional diuresis and antagonize the effects of aldosterone on myocardial fibrosis. An ACE inhibitor, such as enalapril (0.5 mg/kg PO q12h) or benazepril (0.25-0.5 mg/kg PO q12h), is recommended to reduce afterload and modulate neurohormonal activation. Pimobendan, a positive inotrope and vasodilator, may be beneficial in dogs with right-sided heart failure due to its ability to improve myocardial contractility and reduce preload and afterload. The dose is 0.25-0.3 mg/kg PO q12h. In cases with concurrent pulmonary hypertension, sildenafil (1-2 mg/kg PO q8-12h) may be added. Antiarrhythmic therapy may be needed for atrial fibrillation; diltiazem (0.5-1.5 mg/kg PO q8h) or digoxin (0.005-0.01 mg/kg PO q12h) can be used to control ventricular rate. In severe, refractory cases, surgical intervention such as tricuspid valve repair or replacement has been attempted, but it is technically challenging and associated with high morbidity and mortality. Interventional procedures, such as edge-to-edge repair or annuloplasty, are experimental in veterinary medicine. In cases with concurrent patent foramen ovale or atrial septal defect, closure may be considered. Dietary modification with a low-sodium diet is recommended for animals with heart failure. Exercise restriction is advised for symptomatic animals. In asymptomatic animals, regular monitoring with echocardiography every 6-12 months is recommended to assess progression.

The prognosis for tricuspid valve dysplasia is highly variable and depends on the severity of the anatomical lesion, the degree of regurgitation, the presence of concurrent congenital defects, and the response to therapy. Animals with mild regurgitation and no clinical signs may have a normal lifespan, although they are at risk for developing heart failure later in life. Animals with moderate to severe regurgitation often develop right-sided heart failure at a young age, and the prognosis is guarded. In one study, the median survival time for dogs with TVD and right-sided heart failure was approximately 1-2 years with medical management. Negative prognostic indicators include early onset of clinical signs (before 1 year of age), severe right atrial and ventricular enlargement, presence of atrial fibrillation, and poor response to diuretic therapy. Animals with concurrent congenital defects, such as pulmonic stenosis or ASD, have a worse prognosis. Sudden death can occur due to arrhythmias or rupture of the right atrium. With appropriate medical management, many animals can have a good quality of life for months to years. Surgical correction, if successful, may improve prognosis, but it is rarely performed and carries significant risks. Overall, the prognosis is better for animals with mild disease and those that respond well to medical therapy.

Follow-up for animals with tricuspid valve dysplasia should be tailored to the severity of the disease. Asymptomatic animals with mild regurgitation should be re-examined every 6-12 months, including a physical examination, thoracic radiography, and echocardiography to monitor for progression. For animals with clinical signs or moderate to severe regurgitation, more frequent monitoring is recommended, initially every 1-3 months until stable, then every 3-6 months. At each recheck, body weight, heart rate, respiratory rate, and auscultation findings should be recorded. Thoracic radiographs should be repeated to assess cardiac size and the presence of pleural effusion or pulmonary edema. Echocardiography should be performed to evaluate changes in right heart dimensions, regurgitant severity, and systolic function. Serum biochemistry and electrolytes should be monitored regularly, especially in animals on diuretics and ACE inhibitors, to detect azotemia, electrolyte imbalances, or hepatotoxicity. NT-proBNP levels may be monitored to assess the severity of heart failure and response to therapy. Owners should be educated to monitor their pet's resting respiratory rate at home; an increase above 30-40 breaths per minute may indicate worsening heart failure and warrants immediate veterinary attention. Adjustments to medication dosages should be made based on clinical status and laboratory findings. In animals with atrial fibrillation, heart rate control should be assessed with ECG. Long-term management requires a partnership between the veterinarian and the owner to optimize quality of life and detect complications early.

Pearls: 1) Always auscultate the right thorax in addition to the left; a right-sided systolic murmur is a key clue for tricuspid valve disease. 2) In young large-breed dogs with a right-sided murmur, TVD should be high on the differential list, especially in Labrador Retrievers. 3) Echocardiography is essential for diagnosis; do not rely solely on radiography, as the changes may be subtle in mild cases. 4) When measuring the tricuspid regurgitant jet velocity, use the modified Bernoulli equation to estimate pulmonary artery pressure; a velocity >3 m/s suggests pulmonary hypertension. 5) In animals with right-sided heart failure, always evaluate for concurrent congenital defects, as they may alter the prognosis and management. 6) Consider starting pimobendan early in the course of right heart failure, as it may improve clinical signs and survival. Pitfalls: 1) Do not mistake the murmur of TVD for a left-sided murmur; careful auscultation is crucial. 2) Avoid over-diuresis, which can cause prerenal azotemia and electrolyte imbalances; titrate furosemide to the lowest effective dose. 3) Do not ignore the possibility of atrial fibrillation; an irregularly irregular rhythm should prompt an ECG. 4) Do not assume that a dog with ascites and a heart murmur has right-sided heart failure; consider other causes such as pericardial effusion or liver disease. 5) Do not delay referral to a veterinary cardiologist for advanced imaging and management in severe cases. 6) Be cautious with the use of ACE inhibitors in animals with pre-existing renal disease; monitor renal parameters closely.

The following drug protocols are based on Plumb's Veterinary Drug Handbook and current veterinary cardiology guidelines. 1) Furosemide: For acute congestive heart failure, administer 2-4 mg/kg IV or IM initially, then 1-2 mg/kg IV or PO q8-12h. For chronic management, use 1-2 mg/kg PO q8-12h, titrating to the lowest effective dose. Monitor renal function and electrolytes. 2) Spironolactone: 1-2 mg/kg PO q12h, often used in combination with furosemide. Contraindicated in hyperkalemia. 3) Enalapril: 0.5 mg/kg PO q12h, starting at 0.25 mg/kg and titrating up. Monitor renal function and potassium. 4) Benazepril: 0.25-0.5 mg/kg PO q12h. Similar precautions as enalapril. 5) Pimobendan: 0.25-0.3 mg/kg PO q12h, administered at least 1 hour before food. It is contraindicated in hypertrophic cardiomyopathy. 6) Sildenafil: 1-2 mg/kg PO q8-12h for pulmonary hypertension. 7) Diltiazem: For atrial fibrillation, 0.5-1.5 mg/kg PO q8h, or a sustained-release formulation at 3-5 mg/kg PO q24h. 8) Digoxin: 0.005-0.01 mg/kg PO q12h, with therapeutic drug monitoring to maintain serum levels between 0.8-2.4 ng/mL. Use with caution in renal impairment. 9) In cases of acute severe heart failure, oxygen supplementation and thoracocentesis for pleural effusion may be necessary. 10) Antiarrhythmic therapy for ventricular arrhythmias may include sotalol (1-2 mg/kg PO q12h) or amiodarone (10-15 mg/kg PO q12h for 7 days, then 5-10 mg/kg q24h). All dosages should be adjusted based on individual patient response and renal/hepatic function. Drug interactions: Furosemide may enhance the nephrotoxicity of aminoglycosides; ACE inhibitors may increase the risk of hyperkalemia when combined with potassium-sparing diuretics; pimobendan may potentiate the effects of vasodilators.

The veterinary literature on tricuspid valve dysplasia is relatively limited compared to other congenital heart defects, but several key studies and consensus statements provide guidance. A landmark study by Buchanan (1965) first described the pathological features of TVD in dogs. More recent studies have focused on breed-specific prevalence and genetic aspects. A study by Famula et al. (2002) in Labrador Retrievers demonstrated a familial pattern and suggested an autosomal dominant mode of inheritance with incomplete penetrance. A genome-wide association study by Stern et al. (2015) identified a significant locus on canine chromosome 9 associated with TVD in Labrador Retrievers, providing a foundation for future genetic testing. Clinical outcome studies, such as that by Chetboul et al. (2004), reported that dogs with TVD and right-sided heart failure have a median survival time of approximately 1-2 years with medical management. The use of pimobendan in right-sided heart failure has been extrapolated from studies in left-sided heart failure, such as the EPIC trial (2015), which showed improved survival in dogs with myxomatous mitral valve disease; its benefit in TVD is presumed but not specifically studied. The ACVIM consensus statement on the diagnosis and treatment of canine heart disease (2019) provides general guidelines for managing heart failure, including the use of diuretics, ACE inhibitors, and pimobendan. There are no large randomized controlled trials specifically for TVD, and most recommendations are based on expert opinion and extrapolation from other cardiac diseases. Future research should focus on prospective studies of medical therapy and the development of surgical or interventional techniques.